Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $3.92 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.